

E1  
cond

which inserts a NotI site. The 1238 base pair product was digested with EcoRI and NotI and before being ligated in to EcoRI, NotI digested pBAC-1 (Novagen) creating pBACM3. The ORF was

**In the claims:**

E2

17. (Twice Amended) A method of blocking binding of a chemokine capable of binding an M3 protein of MHV68 to a receptor for the chemokine on the surface of a cell, comprising contacting the cell with a M3 protein of MHV68 or functional homologue thereof which binds to the chemokine, thereby blocking the binding of the chemokine to the receptor.

N.E.  
Duplicate

18. (Reiterated) The method of claim 17, wherein the chemokine is a CXC, CC, C, or a CX3C chemokine.

19. (Reiterated) The method of claim 18, wherein the chemokine is a human or a mouse chemokine.

E3

20. (Twice Amended) The method of claim 17, wherein the chemokine is lymphotactin, RANTES, MIP-1 alpha, MCP-1, MCP-4, IL-8, murine KC, murine MIP2, human GCP2, human IP10, fractalkine, murine LIX, MIP-1, or secondary lymphoid tissue chemokine SLC.

N.E.  
Duplicate

22. (Reiterated) The method of claim 17, wherein the cell is *in vitro*.

23. (Reiterated) The method of claim 17, wherein the cell is *in vivo*.

E4

24. (Amended) The method of claim 17, wherein the M3 protein of MHV68 is labeled.

25. (Reiterated) The method of claim 17, wherein the chemokine is labeled.

26. (Reiterated) The method of claim 17, wherein the receptor for the chemokine is labeled.

27. (Reiterated) The method of claim 17, wherein the cell is a skin cell.

N.E.  
Duplicate

ES 28. (Amended) The method of claim 17, wherein the M3 protein of MHV68, or  
homologue is a coupled protein.

Please add the following new claims:

29. (New) The method of claim 17, wherein the chemokine comprises lymphotactin.

30. (New) The method of claim 17, wherein the chemokine comprises RANTES.

31. (New) The method of claim 17, wherein the chemokine comprises MIP-1-alpha.

32. (New) The method of claim 17, wherein the chemokine comprises MCP-1.

33. (New) The method of claim 17, wherein the chemokine comprises MCP-4.

34. (New) The method of claim 17, wherein the chemokine comprises IL-8.

35. (New) The method of claim 17, wherein the chemokine comprises human GCP2.

36. (New) The method of claim 17, wherein the chemokine comprises human IP10.

37. (New) The method of claim 17, wherein the chemokine comprises fractalkine.

38. (New) The method of claim 17, wherein the chemokine comprises secondary lymphoid  
tissue chemokine SLC.

39. (New) The method of claim 17, wherein the chemokine is a human chemokine.

#### REMARKS

Claims 17, 24 and 28 are amended to refer to the M3 protein of MHV68, as supported  
throughout the specification, for example on page 13, lines 27-30. Claim 20 is amended to correct a